ArticleInternational journal of obesity (2005)2025
Gastrointestinal side effects of incretin-based obesity management medications: insights from healthcare professionals and patients' experiences.
Article in International journal of obesity (2005), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal (GI) symptoms are the most frequently reported adverse events of incretin-based Obesity Management Medications (OMMs). There is a lack of comprehensive knowledge and experience regarding the management of GI side effects in patients treated with incretin-based OMMs, highlighting the need to develop practical recommendations. This study aims to gain an in-depth understanding of the perceptions and experiences of patients and healthcare professionals (HCPs) regarding the GI side effects associated with incretin-based OMMs treatment, focusing on the unique perspectives of these two populations.
methodsA qualitative descriptive research design, including two focus group sessions with seven HCPs (physicians and dietitians) and semi-structured interviews with eight patients who are treated with incretin-based OMMs, was performed. The interviews were analyzed using qualitative content analysis.
resultsTwo major themes emerged from the study. The first theme revolves around the different characteristics of GI side effects, encompassing four sub-themes: (1) types of common GI side effects; (2) the timing of GI side effect occurrence; (3) challenges in diagnosis; and (4) their impact on quality of life and treatment continuity. The second theme focuses on strategies for the prevention and management of GI side effects during treatment with incretin-based OMMs encompassing five sub-themes: (1) preliminary education; (2) tailored dose escalation; (3) dietary and lifestyle modifications for the treatment of specific GI symptoms; (4) medical therapy aimed to alleviate symptoms; and (5) multidisciplinary follow-up.
conclusionNewly identified characteristics of GI side effects have emerged, enabling a more comprehensive understanding of the phenomenon. Moreover, HCPs proposed detailed strategies for preventing and managing GI side effects. The insights gained could be beneficial for both HCPs and patients aiming to improve the quality of care and medication adherence.
Indexed as
Identifiers
40877566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.